In a woman older than 60 years considering hormone replacement therapy, what coronary artery calcium (CAC) score should be obtained and how should the result guide treatment decisions?

CAC Scoring for HRT Decision-Making in Women Over 60

In women over 60 considering hormone replacement therapy, obtain a coronary artery calcium (CAC) score to assess subclinical atherosclerotic burden, and use CAC = 0 as reassurance to proceed with HRT if indicated for symptoms, while CAC ≥100 should prompt serious reconsideration of HRT initiation due to established atherosclerosis.

The Critical Age and Timing Issue

Women over 60 face a fundamentally different risk-benefit calculus for HRT than younger postmenopausal women. The "timing hypothesis" is crucial here: HRT initiated more than 10 years after menopause (which applies to most women over 60) shows no cardiovascular benefit and may increase early cardiovascular risk 1. The mean participant age in trials showing null or harmful cardiovascular effects was 65.8 years, with an average of 23.1 years since menopause 1.

How to Use CAC Scoring

Obtain CAC in women over 60 when:

• HRT is being considered for persistent menopausal symptoms
• Cardiovascular risk status is uncertain
• The decision to initiate or continue HRT is unclear

Interpretation Algorithm for HRT Decisions:

CAC = 0:

• Indicates minimal atherosclerotic burden
• Provides reassurance for HRT initiation if symptom management requires it
• Research shows women with long-term HRT use (>15 years) who started within 5 years of menopause have CAC levels <50% of never-users 2
• However, at age >60, the window for primary cardiovascular benefit has likely closed 1

CAC = 1-99:

• Represents mild subclinical atherosclerosis
• Exercise caution with HRT initiation
• Consider alternative symptom management strategies
• If HRT is essential, use lowest effective dose with close monitoring

CAC ≥100:

• This is your hard stop for initiating HRT
• Represents established coronary atherosclerosis 3
• Women with documented coronary stenosis showed no benefit from HRT and possible early increased risk 1
• Strongly favor non-hormonal alternatives for symptom management

CAC >400:

• Absolute contraindication to HRT initiation
• High cardiovascular risk (>20% 10-year risk) 4
• Focus on aggressive cardiovascular risk reduction with statins and lifestyle modification

The Evidence Paradox You Must Understand

There's an apparent contradiction in the literature that requires careful interpretation:

• Observational studies show women who used HRT long-term have lower CAC scores 5, 2, 6
• Randomized trials in older women with established disease show no benefit or harm 1

The resolution: Women who started HRT early (within 5 years of menopause) and continued long-term appear to have less atherosclerosis development. But starting HRT after age 60—when atherosclerosis is already established—does not reverse existing disease and may destabilize plaques 1.

Critical Caveats

The "Healthy User" Bias

Women prescribed HRT historically were healthier, more educated, and had better preventive care 1. CAC scoring helps cut through this bias by providing objective atherosclerotic burden measurement.

What CAC Doesn't Tell You

• Plaque stability: CAC measures calcified plaque, not vulnerable lipid-rich plaques
• Acute risk: A CAC of 0 doesn't eliminate short-term thrombotic risk from HRT
• Non-cardiac risks: CAC doesn't assess stroke or venous thromboembolism risk, both elevated with HRT in older women

Formulation Matters

If HRT is pursued despite elevated CAC:

• Transdermal preparations show safer cardiovascular profiles than oral 7
• Oral estrogen undergoes first-pass hepatic metabolism, increasing prothrombotic factors
• Consider bioidentical hormones over synthetic preparations 7

Practical Management Framework

For women >60 with bothersome symptoms:

1. First: Exhaust non-hormonal options (SSRIs, gabapentin, lifestyle modifications)

2. If HRT still considered necessary:

   • Obtain CAC score
   • Calculate 10-year ASCVD risk using standard calculators

3. Decision matrix:

   • CAC = 0 + low ASCVD risk: May proceed with lowest-dose transdermal HRT
   • CAC = 0 + intermediate/high ASCVD risk: Reconsider; non-hormonal preferred
   • CAC 1-99: Strong preference for non-hormonal management
   • CAC ≥100: Do not initiate HRT

4. If CAC ≥100 is discovered:

   • Initiate statin therapy 3
   • Consider aspirin if CAC >100 4
   • Aggressive lifestyle modification
   • Non-hormonal symptom management only

The Bottom Line

CAC scoring provides objective data to override the outdated practice of routinely prescribing HRT to women over 60. The presence of any significant coronary calcification (≥100) identifies women in whom HRT initiation carries unacceptable cardiovascular risk without proven benefit. A CAC of 0 doesn't guarantee safety but provides relative reassurance if HRT is truly necessary for quality of life, though non-hormonal alternatives should still be strongly preferred in this age group.

The 2023 global CAC guidelines 3 establish clear thresholds for cardiovascular risk stratification that should directly inform HRT decisions, even though these guidelines don't specifically address HRT. When cardiovascular risk assessment indicates established atherosclerosis, symptom management must not come at the cost of increased mortality risk.